Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc.

Overview
Date Founded

1989

Headquarters

1225 Old Highway 8 NW,St. Paul, MN 55112

Type of Company

Public

Employees (Worldwide)

779

Industries

Medical Products & Equipment
IT Consulting & Services
Medical Support Services
Biotechnology
Wholesale: Medical Supplies & Pharmaceuticals
Hospitals & Patient Services

Company Description

Cardiovascular Systems is devoted to developing innovative solutions for treating peripheral and coronary artery disease, to help physicians conquer calcium, one of the largest challenges when treating PAD and CAD and help patients get back to what matters.

Contact Data
Trying to get in touch with decision makers at Cardiovascular Systems, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Chief Operating Officer

General Counsel

Chief Compliance Officer

Chief Medical Officer

Chief Human Resources Officer

Vice President, Investor Relations & Corporate Communications

Vice President, Corporate Development & Intellectual Property

Vice President, Manufacturing & Operations

Board of Directors

President & Chief Executive Officer at Cardiovascular Systems, Inc.

Former Senior Vice President & President, North America at Hill-Rom Holdings, Inc.

Managing Director at HealthCare Ventures LLC

Honorary Co-Chairman at Pass USMCA Coalition

Partner at Health Evolution Management Co. LLC

Senior Vice President-Investments at RBC Wealth Managment

Former Partner at Ernst & Young LLP

Venture Partner at SHVMS, LLC

Vice President-Diversity & Inclusion at St. Jude Children's Research Hospital, Inc.

Paths to Cardiovascular Systems, Inc.
Potential Connections via
Relationship Science
You
Cardiovascular Systems, Inc.
Owners & Shareholders
Details Hidden

BCM provides investment services to clients on an individual basis, taking into consideration each client's investment objectives, goals, circumstances, and investment needs. When selecting securities and determining the total amount to be purchased or sold, the firm observes the investment policies, limitations and restrictions of the client accounts for which it advises. Their primary approach in evaluating securities is fundamental analysis. The investment strategy employed by BCM generally involves establishing long-term positions. The principal drivers for their sell discipline are: (1) when the fundamentals that spurred the original investment change adversely; (2) the security becomes overvalued, or; (3) it is determined that the security has been an investment mistake. Short sales, margin transactions and options (in all forms) are not utilized.

Details Hidden

CIP aims to generate attractive returns with less risk than the overall market by offering institutional separate accounts and pooled investment vehicles, including mutual funds, commingled funds, and a collective investment fund in both US small-cap and mid-cap equity strategies as well as emerging markets all-cap and small-cap equity strategies. The portfolio is comprised of companies that the firm believes have attractive long-term fundamentals, appreciation potential, and valuations.

Details Hidden

GIM is an active manager that employs fundamental bottom-up research to invest in stocks of companies that they believe exhibit a critical combination of superior growth prospects and attractive stock valuations. The firm specializes in small/micro-cap equity securities.

Recent Transactions
Details Hidden

Cardiovascular Systems, Inc. issued USD Common Stock

Details Hidden

Cardiovascular Systems, Inc. issued USD Common Stock

Details Hidden

Cardiovascular Systems, Inc. issued USD Common Stock

Transaction Advisors
Auditor

Advised onCardiovascular Systems, Inc. issued USD Common Stock

Underwriter

Advised onCardiovascular Systems, Inc. issued USD Common Stock

Underwriter

Advised onCardiovascular Systems, Inc. issued USD Common Stock

Legal Advisor

Advised onCardiovascular Systems, Inc. issued USD Common Stock

Managing Director

Advised onCardiovascular Systems, Inc. issued USD Common Stock

Managing Director, Medical Supplies & Devices

Advised onCardiovascular Systems, Inc. issued USD Common Stock

Clients

Medikit Co., Ltd. engages in the manufacture and sale of medical equipment. It operates through the following divisions: Artificial Dialysis, Intravenous Needles, and Angiography. The Artificial Dialysis division includes catheters used for artificial dialysis. The Intravenous Needles division manufactures and sells needles used in blood transfusion and anesthesia. The Angiography division deals with angiography catheters, sheath introducers, and other interventions. The company was founded by Hiroaki Nakajima on June 15, 1973 and is headquartered in Tokyo, Japan.

OrbusNeich Medical Technology Co. Ltd. is a Hong Kong Chinese private company located in Hong Kong. The firm manufactures medical devices. Bruce Wayne Johnson is the current CEO, occupying that position since 2002.The company says this about itself: OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stents, the COMBO Plus and COMBO Dual Therapy Stents, together with stents and balloons marketed under the names of Azule™, Scoreflex™, Sapp hire™ II, Sapp hire™ II PRO and Sapp hire™ II NC, as well as products to treat peripheral artery disease: the Jade™ and Scoreflex™ PTA balloons. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries.

Key Stats and Financials As of 2020
Market Capitalization
$1.41B
Total Enterprise Value
$870M
Earnings Per Share
$-0.79
Revenue
$237M
Net Profit
$-27.2M
EBITDA
$-18.4M
EBITDAMargin
-7.77%
Total Debt
$21.2M
Total Equity
$269M
Enterprise Value / Sales
3.68x
TEVNet Income
-31.96x
Debt TEV
0.02x
Three Year Compounded Annual Growth Rate Of Revenue
4.9%
Enterprise Value EBITDAOperating
510.49x
Five Year Compounded Annual Growth Rate Of Revenue
12.67%
Non-Profit Donations & Grants
Investors
Details Hidden

Easton invests in all segments of the healthcare industry, including biopharmaceuticals, drug delivery, medical devices and healthcare services. They look for high-caliber teams with industry experience and a demonstrated ability to deliver results. Easton assists in identifying and recruiting additional management talent.Easton prefers to invest alongside other strong financial players to provide maximum value to the company and to ensure the availability of adequate growth capital. The firm is stage-agnostic and considers opportunities from early-stage venture capital to later-stage growth capital with investment size ranging from $0.05 - $10 million. They are generally not a seed-stage investor.

Details Hidden

Mitsui & Co. Global Investment focuses on investments in the following sectors: medical/healthcare, clean technology, information technology and consumer services. Within the medical/healthcare sector, the firm invests primarily in pharmaceuticals, medical devices and medical related services. Their clean technology investments include green technology and new energies. Within the information technology sector, Mitsui & Co. Global Investment focuses on Internet technologies/services, software and electronics. The firm's consumer services investments include food service and retail. The firm considers opportunities at all stages of development, provided such opportunities fit within their industry coverage and investment profile. Their investments range from seed stage to formation capital, late-stage venture to growth capital and other private equity deals.

Details Hidden

Maverick Capital’s investment process is driven by intensive, fundamental bottom-up research. They deploy capital to individual investment opportunities that it believes offer the highest returns relative to risk, regardless of index weightings, market capitalization or style orientations. Their research is augmented by a top-down view of individual industries, as well as the efforts of their quantitative research team. While fundamentals still drive security selection, the quantitative research effort plays an important role in Maverick’s portfolio construction, security selection and risk management. The firm’s investment team is organized into six industry sector teams: Consumer, Financials, Healthcare, Industrials, Media & Telecom and Technology. The industry sector teams are supported by two discipline research teams: private investments and quantitative. The firm’s founder – Lee S. Ainslie III – has ultimate responsibility for all portfolio decisions for Maverick Funds and related Separate Account Clients.

Suppliers
OrbusNeich Medical Technology Co. Ltd. Medical Products & Equipment | Hong Kong

OrbusNeich Medical Technology Co. Ltd. is a Hong Kong Chinese private company located in Hong Kong. The firm manufactures medical devices. Bruce Wayne Johnson is the current CEO, occupying that position since 2002.The company says this about itself: OrbusNeich is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products are the world's first dual therapy stents, the COMBO Plus and COMBO Dual Therapy Stents, together with stents and balloons marketed under the names of Azule™, Scoreflex™, Sapp hire™ II, Sapp hire™ II PRO and Sapp hire™ II NC, as well as products to treat peripheral artery disease: the Jade™ and Scoreflex™ PTA balloons. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries.

Allium Medical Solutions Ltd. Hospitals & Patient Services | Caesarea, Israel

Allium Medical Solutions Ltd. engages in the development, manufacture, and sale of long-term, fully covered, expandable, and retrievable stents for the treatment of various obstructions in the urinary and gastrointestinal tract. Its products include ureteric stents, bulbar stents, triangular prostatic stents, round posterior stent, and biliary stents. The company was founded by David Mark Milch on January 4, 2004 and is headquartered in Caesarea, Israel.

Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Boston Scientific Corporation Medical Products & Equipment - Marlborough, MA

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Abbott Laboratories Pharmaceuticals - Abbott Park, Illinois

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Cardiovascular Systems, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Cardiovascular Systems, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Cardiovascular Systems, Inc..